Regular contributor Dr. MedLaw discusses the question many physicians are asking themselves: what are the rules regarding AI use in medicine and physician liability? Also, Saby George, MD, FACP (Roswell Park Cancer Institute), discusses results of the Checkmate 67T trial, which he recently presented at the 2024 ASCO Genitourinary Cancers symposium. The study compared subcutaneous nivolumab with intravenous nivolumab in patients with advanced kidney cancer. Dr. George reviews the impact the trial results will have on all cancer types with nivolumab in their treatment arsenal.

Enjoy Listening!